Biologics API Market

Market Outlook

The global biologics API market size, valued at USD 70.4 billion in 2025, is projected to reach USD 78.4 billion in 2026 and USD 153.8 billion by 2035, representing a CAGR of 8% during the forecast period, 2026 to 2035. The growth in the market is driven by increasing prevalence of chronic diseases, accelerating demand for complex and high-value biologics, and the widespread adoption of advanced manufacturing technologies.

Market Report: Summary

• The global biologics API market growth is driven by the unmet need for highly effective therapies targeting complex and chronic diseases such as cancer, autoimmune disorders, diabetes and rare conditions. The market is projected to reach USD 153.8 billion by 2035, indicating a substantial expansion.
• Monoclonal antibodies currently hold the largest market share due to their wide therapeutic use, proven clinical efficacy, and the high commercial success of blockbuster drugs in oncology, autoimmune, and infectious conditions.
• The mammalian expression system dominates the market, accounting for the highest share. This is attributed to the fact that mammalian expression systems can produce proteins with proper folding and post-translational modifications, which are essential for biological activity, stability and efficacy.
• Stainless steel bioreactors are capturing majority of the market share. However, the single-use bioreactors segment is likely to grow at a relatively higher CAGR owing to the various advantages offered by these bioreactors, including cost saving potential, improved performance / efficiency and elimination of potent liquid waste.
• Commercial scale production currently dominates the market due to the growing demand for various biologics, including cell and gene therapies, vaccines, bispecific antibodies and ADCs. Further, this segment is likely to grow at relatively higher CAGR by 2035.
• In-house manufacturers segment accounts for majority share of the market. This is attributed to the increasing acquisition and investment activity by the drug developers in order to expand their capacity and capabilities for API pharmaceutical production.
• North America is currently the market leader due to its high rate of technological innovation and robust research initiatives.

Market Overview

Biologics active pharmaceutical ingredients (API) refer to the biologically active components of biological drugs responsible for producing the desired therapeutic effects in the patient. These biologically active ingredients of the therapies are produced using several biotechnological methods / techniques, such as recombinant DNA technology. It is worth mentioning that till date, more than 400 biologics are approved by the FDA, including monoclonal antibodies, mRNA therapeutics and vaccines, and bispecific antibodies. Notably, global shift towards personalized treatment has accelerated interest and investment in the biologics API industry.

Several large biopharmaceutical players, such as Novartis, Pfizer, Roche and Eli Lilly are supporting the active pharmaceutical ingredient manufacturing in their in-house API manufacturing facilities for the efficient production of various biologics. Further, significant developments are taking place in the biologic manufacturing domain. In April 2025, Merck announced the construction of 470,000-square-foot state-of-the-art biologics center of excellence in Wilmington, Delaware for the commercial production of next-generation biologics and therapies including potent antibody-drug conjugates (ADCs). In parallel, fermenters and bioreactors provide the controlled culture environment required for scalable biologics and cell-based production.

As more biologics evolve and receive approval from the regulatory organizations, it is expected that API production will grow, along with biologic developers producing the active pharmaceutical ingredients in their own manufacturing facilities. Further, in order to meet the biologics demand, the API manufacturing is also outsourced to contract manufacturers, resulting in biologics API CDMO market opportunity.

Market Segmentation Insights

Market Share by Type of Expression System: Mammalian Expression Systems are Likely to Drive the Demand

• This segment highlights three types of expression systems, including mammalian (CHO, Vero and HEK), microbial (E. Coli and yeast) and other expression systems.
• According to the biologics API market report, in 2026, the mammalian expression system segment is dominating the market by occupying over 75% of the overall revenue share. Further, presently mammalian expression system holds 90%, 86%, 77%, 75%, 54%, 94% and 70% of the overall ADC API market, cell and gene therapy API market, monoclonal antibody API market, biosimilars API market, vaccines API market, bispecific antibody API market and protein-peptide API market, respectively.
• The other expression systems segment is likely to register higher CAGR. This can be attributed to the growing usage of plant and insect cell lines for the production of various biologics, including protein-peptide therapeutics.

Market Share by Region: How is the Regional Opportunity Distributed?

North America: Remains the Center for Technological Innovations

Currently, North America dominates the market and is likely to remain same in the future. This growth is due to the presence of leading drug developers and manufacturers, advanced healthcare infrastructure and robust research and development (R&D) capabilities in this region, fostering continuous development for personalized treatment. Further, the high prevalence of chronic diseases in this region has led to increasing government initiatives for the development of innovative therapeutics.

Asia-Pacific: Emerging as a Hotspot for Biologic API Manufacturing

According to the biologics API industry analysis, the Asia-Pacific region is likely to show robust growth in the future. This is attributed to the expanding pharmaceutical API manufacturing capacities in Asia-Pacific countries, including China, India and South Korea. Further, the availability of skilled workforce with cost-effective production in this region is driving the growth of biologic API production in this region. Further, increasing government investments in biotech infrastructure and growing adoption of biosimilars also accelerates the regional demand and development for biologics API application pipeline.

Industry Experts on Biologics Active Pharmaceutical Ingredients Market

Experts believe that extensive experience of the manufacturer in the domain helps to navigate several challenges associated associated with the complex production process of biologic APIs.

During an interview, Simone Seechi (R&D Process Chemist, Olon) stated that, “One of the key challenges in ADC manufacturing is its evolving regulatory landscape. These therapies combine biological and small molecules, requiring extensive data on pharmacokinetics, toxicity, and efficacy. The complexity of ADCs demands highly specialized testing and validation processes. With its extensive experience and proven track record across all stages of the API lifecycle, companies are well equipped to navigate these challenges”

Key Market Insights

Market Drivers: Rapidly Growing Biologics Demand

• It is worth mentioning that in the past few years, the market has witnessed approval for new biologics. In 2024, FDA alone approved 42 biologics (18 under CDER and 24 under CBER). As such, these increasing regulatory approvals are driving the demand for biologic APIs. Majority of the biologics API market share (by volume) based on type of modalities is captured by monoclonal antibodies (~70%). This is followed by APIs manufactured for efficient production of protein-peptide therapeutics and biosimilars.
• Additionally, the commercial demand for cell and gene therapies is increasing significantly. It is worth mentioning that the cell therapy demand is likely to reach more than 400,000,000 cells by 2035. This growing demand is driven by several key factors including the rising global incidence of chronic and oncological disorders, increasing FDA approvals for CAR T-cell and other cellular therapies, and growing adoption of personalized and regenerative medicine approaches.

Market Opportunity: Rising Need for Specialty and High-Potency APIs (HPAPIs)

Notably, the specialty and high potency APIs are the key drivers for next-generation biologics and personalized medicine. In order to treat the increasing target patient population for various chronic disorders, highly targeted and effective therapies are required, fueling the growth of HPAPIs, which are potent compounds essential for innovative biologic drugs, including large molecules, antibody-drug conjugates (ADCs), and other targeted therapeutics. It is worth mentioning that regulatory requirements for stringent safety and containment protocols necessitate advanced manufacturing facilities with high-containment capabilities for API production. This has led several biopharmaceutical companies to increasingly outsource API manufacturing to specialized contract manufacturing organizations due to the complex safety, containment, and technical requirements of API synthesis.

Biologics API Industry: Scope of the Report

[Available on request]